High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell–Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia  by Ponce, Doris M. et al.
Biol Blood Marrow Transplant 21 (2015) 1985e1993Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgHigh Disease-Free Survival with Enhanced Protection against
Relapse after Double-Unit Cord Blood Transplantation When
Compared with T CelleDepleted Unrelated Donor
Transplantation in Patients with Acute Leukemia and Chronic
Myelogenous LeukemiaDoris M. Ponce 1,2,*, Patrick Hilden 3, Sean M. Devlin 3, Molly Maloy 1, Marissa Lubin 1,
Hugo Castro-Malaspina 1,2, Parastoo Dahi 1,2, Katharine Hsu 1,2, Ann A. Jakubowski 1,2,
Nancy A. Kernan 4, Guenther Koehne 1,2, Richard J. O’Reilly 4, Esperanza B. Papadopoulos 1,2,
Miguel-Angel Perales 1,2, Craig Sauter 1,2, Andromachi Scaradavou 4, Roni Tamari 1,2,
Marcel R.M. van den Brink 1,2, James W. Young 1,2, Sergio Giralt 1,2, Juliet N. Barker 1,2,*
1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Medicine, Weill Cornell Medical College, New York, New York
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
4Bone Marrow Transplantation Service, Department of Pediatrics; Memorial Sloan Kettering Cancer Center, New York, New YorkArticle history:
Received 1 April 2015
Accepted 28 July 2015
Key Words:
Unrelated donor
transplantation
Cord blood transplantation
Acute leukemia
HLA matchFinancial disclosure: See Acknowle
* Correspondence and reprint
Ponce, Box 259, 1275 York Avenue
E-mail addresses: ponced@msk
(J.N. Barker).
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Double-unit cord blood (DCB) grafts are a rapidly available stem cell source for adults with high-risk leu-
kemias. However, how disease-free survival (DFS) after DCB transplantation (DCBT) compares to that of
unrelated donor transplantation (URDT) is not fully established. We analyzed 166 allograft recipients (66 8/8
HLAematched URDT, 45 7/8 HLAematched URDT, and 55 DCBT) ages 16 to 60 years with high-risk acute
leukemia or chronic myelogenous leukemia (CML). URDT and DCBT recipients were similar except DCBT
recipients were more likely to have lower weight and non-European ancestry and to receive intermediate-
intensity conditioning. All URDT recipients received a CD34þ celleselected (T celledepleted) graft. Overall,
differences between the 3-year transplantation-related mortality were not signiﬁcant (8/8 URDT, 18%; 7/8
URDT, 39%; and DCBT, 24%; P ¼ .108), whereas the 3-year relapse risk was decreased after DCBT (8/8 URDT,
23%; 7/8 URDT, 20%; and DCBT 9%, P ¼ .037). Three-year DFS was 57% in 8/8 URDT, 41% in 7/8 URDT, and 68%
in DCBT recipients (P ¼ .068), and the 3-year DFS in DCBT recipients was higher than that of 7/8 URDT
recipients (P ¼ .021). In multivariate analysis in acute leukemia patients, factors adversely associated with DFS
were female gender (hazard ratio [HR], 1.68; P ¼ .031), diagnosis of acute lymphoblastic leukemia (HR, 2.09;
P ¼ .004), and 7/8 T celledepleted URDT (HR, 1.91; P ¼ .037). High DFS can be achieved in adults with acute
leukemia and CML with low relapse rates after DCBT. Our ﬁndings support performing DCBT in adults in
preference to HLA-mismatched T celledepleted URDT and suggest DCBT is a readily available alternative to
T celledepleted 8/8 URDT, especially in patients requiring urgent transplantation.
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Unrelated donor cord blood (CB) is now routinely used as
a source of allogeneic hematopoietic stem cells (HSC) for thedgments on page 1991.
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ty for Blood and Marrow Transplantation.transplantation of patients with hematologic malignancies.
The reduced stringency of required HLA match in CB trans-
plantation (CBT) has successfully extended transplantation
access to racial and ethnic minorities [1-3]. This is in contrast
to unrelated donor (URD) transplantation (URDT), in which
the requirement for a closely HLA alleleematched volunteer
greatly restricts its application in non-European patients and
those with mixed origins [1-3]. CBT also has the advantages
of rapid availability and ﬂexibility of patient admission,
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availability.
Double-unit CB (DCB) transplantation (DCBT) has ach-
ieved high rates of sustained donor engraftment, partially
mitigating the adverse effect of low total nucleated cell (TNC)
dose in adults [2,4-8]. Moreover, retrospective analyses and 1
randomized study have demonstrated low rates of relapse
after DCBT, predominantly in adult patients [5,9-12]. Adult
DCBT has also been associated with a low rate of late post-
transplantation mortality [6,13]. However, it is associated
with prolonged hospitalization early after transplantation,
the high cost of purchasing 2 units, and increased risk of
early transplantation-related mortality (TRM) [13], limiting
its wide application. Consequently, most transplantation
centers select an 8 HLA alleleematched URD as the standard
HSC source in the absence of a matched sibling donor.
Moreover, some centers prefer a 7/8 HLAematched URD over
a CB graft, especially in view of the rapid count recovery
associated with peripheral blood HSC. The validity of this
donor algorithm is not established, however, especially in
centers with a high degree of expertise in the practice of both
URDT and CBT. Therefore, we compared disease-free survival
(DFS) in 66 8/8 HLAematched URDT, 45 7/8 HLAematched
URDT, and 55 DCBT recipients ages 16 to 60 years with high-
risk acute leukemia and advanced chronic myelogenous
leukemia (CML) who received their transplants over the
same time period with similar supportive care. Our hy-
pothesis was that the 3-year DFS after DCBT is higher than
that of 7/8 HLAematched URDT.
METHODS
Patients Characteristics
Patients underwent transplantation at Memorial Sloan Kettering Cancer
Center between October 2005 and November 2012. During the study period,
8/8 HLAematched URDwere given priority as the optimal donor. Otherwise,
a 7/8 URD (mismatched at either the antigen or allele level) or double-
unit CB grafts were selected according to transplantation urgency, speed
of donor availability, and physician preference. All patients provided written
informed consent for transplantation, outcome analysis was approved
by the Memorial Sloan Kettering Cancer Center institutional review/
privacy board, and patients included in this analysis underwent
transplantation on ClinicalTrials.gov NCT00587054, NCT00582933, NCT00
597519, NCT00629798, NCT00739141, NCT01119066, and NCT00387959
trials. Eligible patients for this analysis included all consecutive patients ages
16 to 60 years who received their ﬁrst myeloablative allograft for the
treatment of acute leukemia, including acute myelogenous leukemia (AML),
acute lymphoblastic leukemia (ALL), undifferentiated or acute biphenotypic
leukemia in morphologic remission or aplasia, or patients who had
advanced CML. CB units were 4 to 6/6 HLA-A, -B antigen, -DRB1 allele
matched to the recipient and had a cryopreserved TNC dose of at least 1.5 
107/kg/unit. The bank of originwas considered in unit selection, whereas the
unit-unit HLA-match was not [8,14]. Comorbidity scores were assigned ac-
cording to Sorror et al. [15].
Conditioning Regimens and Immunosuppression
Pretransplantation conditioning varied according to patient’s age,
diagnosis, remission status, and comorbidities, and consisted of high-dose
or intermediate-intensity regimens. All intermediate-intensity regimens
were functionally myeloablative. In URDT, the conditioning was either
total body irradiation (TBI)-based with thiotepa/ﬂudarabine/TBI (1375 to
1500 cGy), or thiotepa/cyclophosphamide/TBI (1320 to 1500 cGy), or was
chemotherapy-based (clofarabine/thiotepa/melphalan). The intermediate-
intensity regimen consisted of busulfan/ﬂudarabine/melphalan as previ-
ously described [16-20], and all patients received antithymocyte globulin
(ATG). In DCBT, high-dose conditioning consisted of TBI-based regimens
(1320 to 1375 cGy) with high-dose cyclophosphamide and ﬂudarabine, or
less commonly a chemotherapy-based regimen of clofarabine/thiotepa/
melphalan. The intermediate-intensity DCBT regimen was 400 cGy of TBI
combined with cyclophosphamide/ﬂudarabine/thiotepa as previously
described [8,13,21]. URD recipients underwent ex vivoT-cell depletion (TCD)
using CD34þ cell selection of peripheral blood HSC with either the Isolex
300i Magnetic Cell Separator (Baxter, Deeﬁeld, IL) and subsequent sheep redblood cell rosette depletion, or the CliniMACS CD34 reagent system (Mil-
tenyi Biotech, Gladbach, Germany) [20]. Bone marrow was used in a small
minority of patients and was TCD using soybean lectin agglutination and
sheep red blood cell rosette depletion [16]. All DCBT recipients received a
calcineurin inhibitor (predominantly cyclosporine A) and mycophenolate
mofetil starting on day 3 intravenously and none received ATG [13,22].
Granulocyte colonyestimulating factor was given to all URDT and DCBT
recipients after transplantation to promote neutrophil recovery. All patients
received similar supportive care.
Study Deﬁnitions and Statistical Analysis
Time to neutrophil recoverywas deﬁned as the ﬁrst of 3 consecutive days
with a sustained absolute neutrophil count .5  109/L. Time to platelet
recoverywas deﬁned as the ﬁrst of 3 consecutive days at 20  109/L and at
least 7 days without platelet transfusion support. Primary graft failure was
the lack of donor-derived neutrophil recovery by day 45, death from day 28
but before day 45 without neutrophil recovery, or requirement for either a
boost from the same URD or a second transplantation for lack of count re-
covery. Secondary graft failure was deﬁned as a fall in absolute neutrophil
count to <.5  109/L for 14 consecutive days after donor-derived neutro-
phil recovery, requirement for a HSC boost from the same URD, or a second
transplantation as therapy for severe cytopenias after initial engraftment.
Graft-versus-host disease (GVHD) was diagnosed clinically with histo-
logic conﬁrmation when appropriate. Acute and chronic GVHD were graded
according to International Bone Marrow Transplant Registry (grades A to D)
[23] and the National Institutes of Health consensus criteria [24], respec-
tively. Acute and chronic GVHD in URDT were analyzed according to graft
manipulation (CD34þ-selected versus unmodiﬁed grafts). Relapse was
deﬁned as recurrence of leukemia after transplantation and TRM was
deﬁned as death from any cause in continued remission except for de novo
or recurrence of solid tumor malignancies after allograft (n ¼ 3). Overall
survival (OS) and DFS were deﬁned according to standard criteria. The
primary cause of death was deﬁned according to the algorithm of Copelan
et al. [25].
Patient and graft characteristics were compared using chi-square or
Fisher’s exact test for categorical variables as appropriate and the Wilcoxon
rank-sum test for continuous variables. Cumulative incidence functions
were used to estimate neutrophil and platelet engraftment, GVHD, relapse,
and TRM. The competing risks for each outcome were death for engraft-
ment, death or relapse for GVHD, death in the absence of relapse for relapse,
and relapse for TRM. Gray’s test compared the cumulative incidence across
patient and treatment characteristics. OS and DFS were calculated using
Kaplan-Meier methodology and were compared using a log-rank test. Tests
for a difference in OS and DFS between URDT and DCBT reﬂect testing for a
speciﬁc difference in survival probabilities at a ﬁxed time point [26]. All
multivariate models for DFS were ﬁt using weighted Cox regression to ac-
count for potential violations in proportional hazards [27]. Covariates in the
model included patient or disease characteristics with a signiﬁcant or
trending association in either URDT and/or DCBT. All analyses were done
using the R statistical package version 3.1.1 (R Development Core Team, 2011,
Vienna, Austria).
RESULTS
Patient and Graft Characteristics
Table 1 summarizes patient and graft characteristics.
URDT and DCBT recipients had similar age, gender, recipient
with cytomegalovirus (CMV) seropositivity, and hemato-
poietic cell transplantationespeciﬁc comorbidity index
(HCT-CI) scores. DCBT recipients were more likely to have
lower weight, be of non-European ancestry, and receive
intermediate-intensity conditioning. The median times from
diagnosis to HSC transplantation for patients in ﬁrst com-
plete remission (CR1) were similar at 5 months in URDT and
5.1 months in DCBT, as were the times to transplantation
from relapse for patients in CR2 (URDT, 4.2months and DCBT,
3.4 months), and in CR3 (URDT, 3.4 months and DCBT, 3.9
months).
Diagnoses and disease risk were also comparable in URDT
and DCBT recipients. Of patients with previously detected
cytogenetic and/or molecular abnormalities at diagnosis,
14 of 57 (25%) 8/8 HLAematched URDT, 11 of 35 (31%) 7/8
HLAematched URDT, and 13 of 40 (33%) DCBT recipients in
morphologic remission had measurable minimal residual
disease before transplantation. Overall, AML was the most
Table 1
Patient and Graft Characteristics in URDT and DCBT Recipients
Characteristic 8/8 URDT (n ¼ 66) 7/8 URDT (n ¼ 45) DCBT (n ¼ 55) P Value
Age, median (range), yr 50 (16-60) 42 (16-60) 42 (16-60) .087
Male 40 (61%) 23 (51%) 26 (47%) .317
Weight, median (range), kg 77 (40-144) 82 (40-119) 69 (45-96) .010
Recipient CMVþ 37 (56%) 24 (53%) 36 (66%) .417
Recipient ancestry <.001
European 54 (82%) 29 (64%) 25 (46%)
Non-European 12 (18%) 16 (36%) 30 (55%)
HCT-CI score 0-1: 22 (33%) 0-1: 16 (36%) 0-1: 15 (27%) .933
2: 14 (21%) 2: 8 (18%) 2: 9 (16%)
3: 14 (21%) 3: 10 (22%) 3: 14 (26%)
4: 16 (24%) 4: 11 (24%) 4: 17 (31%)
Median 2 (range, 0-8) Median 2 (range, 0-7) Median 3 (range, 0-8)
Diagnosis -
AML* 44 (67%) 29 (64%) 36 (65%)
CR1 31 20 24
CR2-3 13 9 12
ALL 17 (26%) 13 (29%) 17 (31%)
CR1 14 6 7
CR2-4 3 7 10
CML 5 (8%) 3 (7%) 2 (4%)
Conditioning .010
High dose 48 (73%) 31 (69%) 26 (47%)
Intermediate intensity 18 (27%) 14 (31%) 29 (53%)
GVHD prophylaxis -
TCD 66 (100%) 45 (100%) -
CNI/MMF - - 55 (100%)
Infused CD34þ dose, median (range) 5.7  106/kg (.7-17.5) 6.3  106/kg (1.2-14.2) Larger unit:
1.3  105/kg (.3-4.2)
Smaller unit:
.7  105/kg (.2-1.4)
-
CNI indicates calcineurin inhibitor; MMF, mycophenolate mofetil.
Data presented are n (%), unless otherwise indicated.
* Biphenotypic and undifferentiated acute leukemias were included with AML.
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and DCBT recipients who underwent transplantation in CR1
(35 of 51, 69% versus 16 of 24, 67%, respectively) had high-
risk diagnoses. Speciﬁcally, the 35 high-risk URDT AML CR1
patients included 14 with prior myelodysplastic syndromes
or myeloproliferative diseases, 5 with therapy-related dis-
ease, 6 with FLT3-ITD mutations, and 10 with high-risk
chromosomal abnormalities. High-risk CR1 AML DCBT re-
cipients included 6 with prior myelodysplastic syndromes or
myeloproliferative diseases, 2 with therapy-related diseases,
6 with FLT3-ITD mutations, and 2 with high-risk chromo-
somal abnormalities.
URDT and DCBT patients with ALL were also high risk.
URDTpatients included9Philadelphia chromosomeepositive
patients, 5 with complex karyotype or t(4;11), and 6 with
intermediate or normal cytogenetics. Five DCBT recipients
were Philadelphia chromosome positive, 1 had high-risk
cytogenetics, and 1 was previously refractory to multiple
chemotherapy cycles. Twelve URDTand DCBT recipients with
CML had preceding accelerated or blast crisis (n ¼ 6), or had
failed (n ¼ 4) or were intolerant to multiple tyrosine kinase
inhibitors (n ¼ 2). Eleven of these patients were positive for
the Philadelphia chromosome by karyotype or ﬂuorescent in
situ hybridization or BCR/ABL positive by molecular studies
immediately before transplantation.
High-dose conditioning was more common in URDT re-
cipients whereas over one half of the patients in the DCBT
group received a preparative regimen of intermediate in-
tensity (Table 1). The majority of URDT recipients received
peripheral blood HSC (107 of 111, 96%), and CD34þ cell se-
lectionwas done by using Isolex (n¼ 60) or Miltenyi (n¼ 43)
columns or soybean lectin agglutination and sheep red bloodcell rosette depletion (n ¼ 8). DCBT recipients received cal-
cineurin inhibitorebased prophylaxis.
Approximately two thirds of the URDT recipients received
an 8/8 HLAematched graft. DCBT recipients received grafts
with a high degree of HLA disparity and the units had greater
than a log less CD34þ cells. Of the 110 CB units transplanted,
4 (4%) were 6/6, 51 (46%) were 5/6, and 55 (50%) were 4/6
HLA-A, -B antigen, -DRB1 allele HLA matched to the recip-
ient. At 8 HLA alleles, over one third of CB units were only 2
to 4 of 8 HLA allele matched to the recipient (7 to 8/8: 12
[11%], 5 to 6/8: 53 [48%], 2 to 4/8: 45 [41%]), and the median
donor-recipient HLA allele match was 5/8 (range, 2 to 8/8).
The median infused TNC dose in DCBT recipients was 2.62 
107/kg and 1.93  107/kg in the larger and smaller units,
respectively. DCB grafts had greater than a log less CD34þ
cells than URD grafts (Table 1).
The median follow-up of survivors was 3 years 11 months
(range, 14 to 98 months) in 8/8 HLAematched URDT re-
cipients, 4 years 10 months (range, 17 to 98 months) in 7/8
HLAematched URDT recipients, and 3 years 10 months
(range, 15 to 92 months) in DCBT recipients.
Neutrophil and Platelet Engraftment
The cumulative incidence of primary neutrophil engraft-
ment was 100% in 8/8 URDT, 100% in 7/8 URDT, and 95% in
DCBT recipients, whereas the speed of neutrophil recovery
was faster in 8/8 and 7/8 URDT than it was in DCBT recipients
(P < .001, Table 2). Primary graft failure was seen in 2 DCBT
recipients. These patients had 100% bone marrow donor
chimerism but failed to recover counts before their deaths
on days 30 and 35 after allograft in the setting of early
onset multiorgan failure. Although no URDT recipients had
Table 2
Cumulative Incidence of Engraftment and GVHD
Outcome 8/8 URDT (95% CI) (n ¼ 66) 7/8 URDT (95% CI) (n ¼ 45) DCBT (95% CI) (n ¼ 55) P Value
Neutrophil engraftment, d 45 100% (95-100)
Median 11 days
(range, 8-15)
100% (92-100)
Median 11 days
(range, 9-19)
95% (80-99)
Median 24 days
(range, 13-40)
<.001
Secondary graft failure, n (%) 1 (2%) 4 (9%) - -
Platelet engraftment, d 180 99% (69-100)
Median 18 days
(range, 10-48)
96% (79-99)
Median 19 days
(range, 14-43)
86% (71-93)
Median 48 days
(range, 21-162)
<.001
Grade II-IV
aGVHD, d 100
14% (7-23) 18% (8-30) 55% (40-67) .001
Grade III-IV
aGVHD, d 100
6% (2-14) 7% (2-17) 13% (6-23) .832
cGVHD,* 3 yr 8% (3-16) 7% (2-17) 11% (4-21) .707
aGVHD indicates acute GVDH; cGVHD, chronic GVHD.
* The severity of cGVHD after TCD URDT was mild (n ¼ 5) or moderate (n ¼ 3). DCBT recipients had mild (n ¼ 2) or moderate (n ¼ 4) disease.
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in 5 (4%) URDT recipients (1 8/8 HLAematched, 4 7/8
HLAematched). Four received CD34þ celleselected boosts
and 1 received ATG to facilitate count recovery. In DCBT re-
cipients, sustained engraftment was mediated by a single
unit in nearly all patients as previously described [7,8], with
the engrafting unit having a median viable infused CD34þ
cell dose of 1.3  105/kg (range, .3 to 4.2). The cumulative
incidences of platelet engraftment at day 180 were 99%, 96%,
and 86% in 8/8 URDT, 7/8 URDT, and DCBT recipients,
respectively, with more rapid recovery in URDT than in DCBT
recipients (P < .001, Table 2). Of the 51 DCBT recipients alive
at day 100, all but 1 had platelet recovery before day 180.Acute and Chronic GVHD
Recipients of 8/8 and 7/8 TCD URD grafts had lower in-
cidences of grade II to IV (grades B to D) acute GVHD at day
100, 14% and 18%, respectively, whereas DCBT recipients had
an incidence of 55% (P¼ .001, Table 2). The day 100 incidence
of grade III and IV acute GVHD, however, was similar among
the groups (6%, 8/8 URDT; 7%, 7/8 URDT; and 13%, DCBT),
P ¼ .832. The 3-year cumulative incidence of chronic GVHD
was also similar in the 3 groups (P ¼ .707, Table 2).Figure 1. Comparison of the cumulative incidence of 3-year TRM in adult 8/8
HLAematched URDT, 7/8 HLAematched URDT, and DCBT recipients. Overall,
differences between the 3-year TRM were not signiﬁcant (8/8 URDT, 18%; 7/8
URDT, 39%; DCBT, 24%; P ¼ .108).TRM
The 3-year TRM incidences after 8/8 URDT, 7/8 URDT, and
DCBTare compared in Figure 1. The day 180 TRMwas 8% (95%
conﬁdence interval [CI], 3 to 16) in 8/8 URDT, 11% (95% CI, 4
to 22) in 7/8 URDT, and 22% (95% CI, 12 to 34) in DCBT re-
cipients. Overall, differences between the 3-year TRM were
not signiﬁcant (8/8 URDT, 18% [95% CI, 10 to 29]; 7/8 URDT,
39% [95% CI, 24 to 53]; DCBT, 24% [95% CI, 13 to 36]; P ¼ .108).
The most common cause of TRM in URDT recipients was
GVHD (3 had grade II, 3 grade III and IV, and 7 had late acute),
Table 3. Four of the patients received 8/8 HLAematched URD
and 9 received 7/8 HLAematched URD grafts and most
deaths occurred after day 180. The second most common
cause of death was infection in 12 URDT recipients (4 bac-
terial, 1 CMV, 3 adenovirus, 1 BK virus, 1 progressive multi-
focal leukoencephalopathy, and 2 with Epstein-Barr virus
post-transplantation lymphoproliferative disease).
GVHD was also the most common cause of death in 5
DCBT recipients with the second most common cause of
death being organ failure (3 pulmonary,1 cardiac). Death due
to primary graft failure occurred in 2 patients and infection
was relatively uncommon as a primary cause of death after
DCBT (n ¼ 2). No DCBT recipient developed or died of CMVpneumonia although all patients who died of GVHD also had
CMV viremia or CMV gastrointestinal disease.
Relapse
The cumulative incidence of relapse at 3 years was
decreased after DCBT (8/8 URDT, 23% [95% CI, 12 to 32]; 7/8
URDT, 20% [95% CI, 8 to 30]; DCBT, 9% [95% CI, 3 to 19];
P ¼ .037) (Figure 2, Table 3). Of 26 relapsing URDT recipients,
16 had AML (11 CR1, 5 CR2), 9 had ALL (5 CR1, 1 CR2, 3 CR3),
and 1 had CML. The majority (22 of 26, 85%) received high-
dose conditioning. Three URDT recipients received donor
lymphocyte infusions for the treatment of relapse. In DCBT, 4
patients relapsed (2 CR1 AML [1 FLT3 mutation and 1 sec-
ondary AML], and 2 ALL [1 CR1, 1 CR3]), and all had received
intermediate-intensity conditioning.
3-Year OS and DFS
The 3-year OS were 57% (95% CI, 44 to 69) in 8/8 URDT,
44% (95% CI, 29 to 56) in 7/8 URDT, and 73% (95% CI, 59 to 83)
in DCBT recipients (P ¼ .067 by log-rank). The 3-year DFS in
8/8 URDT (57%; 95% CI, 45 to 68), 7/8 URDT (41%; 95% CI, 27 to
55), and DCBT recipients (68%; 95% CI, 53 to 79) are shown in
Figure 3. The overall comparison of the 3 groups by log-rank
was P ¼ .068. However, DCBT recipients had a higher 3-year
Figure 3. Comparison of the Kaplan-Meier estimate of 3-year DFS in adult 8/8
HLAematched URDT, 7/8 HLAematched URDT, and DCBT recipients. Three-
year DFS was 57% in 8/8 URDT, 41% in 7/8 URDT, and 68% in DCBT recipients
(P ¼ .068) overall, whereas the 3-year DFS in DCBT recipients was higher than
that of 7/8 URDT recipients (P ¼ .021).
Table 3
Comparison of Early and Late Causes of Treatment Failure after URDT and
DCBT
Events 8/8 URDT
(28/66, 42%)
7/8 URDT
(26/45, 58%)
DCBT
(17/55, 31%)
Before d 180
TRM 5 (8%) 5 (11%) 12 (22%)
Graft failure - - 2
GVHD - 1 4
Organ failure 1 - 4
Infection 4 3 2
Other* - 1 -
Relapse 1 (2%) 3 (7%) 1 (2%)
After d 180
TRM 9 (14%) 12 (27%) 1 (2%)
Graft failure - 1 -
GVHD 4 8 1
Organ failure 1 - -
Infection 2 3 -
Other* 2 - -
Relapse 13 (20%) 6 (13%) 3 (5%)
* Other included 1 patient who died prior to day 180 of leukoencephal-
opathy of unknown etiology, 1 with recurrent breast cancer and 1 who died
of secondary malignancy after day 180.
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rank (P ¼ .021). The difference between these 2 groups at
3 years after transplantation was also signiﬁcant (P ¼ .01,
Figure 3), whereas there was no difference between the
3-year DFS in 8/8 URDT and DCBT recipients (P¼ .259). There
was no difference in DFS between recipients of Isolex-
selected versus Miltenyi-selected URD grafts (data not
shown).
Univariate and Multivariate Analyses of Determinants of
DFS by HSC Source and All Patients Combined
Further analysis was performed to evaluate risk factors of
DFS individually by HSC source (Tables 4A,B), and in the
entire patient population (Table 5). Three-year DFS esti-
mates, univariate DFS analyses, and multivariate DFS
analyses according to patient and graft variables by source
are shown (Tables 4A,B). In multivariate analyses, CML pa-
tients were excluded to enable a better understanding of the
variables affecting DFS in patients with acute leukemia, theFigure 2. Comparison of the cumulative incidence of 3-year relapse in adult 8/8
HLAematched URDT, 7/8 HLAematched URDT, and DCBT recipients. The
3-year relapse risk was decreased after DCBT (8/8 URDT, 23%; 7/8 URDT, 20%;
DCBT 9%; P ¼ .037).bulk of the patient cohort in each group. In URDT recipients
(Table 4A), a diagnosis of ALL had signiﬁcantly higher risk
of treatment failure. In DCBT recipients (Table 4B), multi-
variate analysis revealed female gender and ALL diagnosis
were associated with a higher risk of treatment failure. As
conditioning intensity was not signiﬁcant in the univariate
analysis in either URT or DCBT, it was not included in the
multivariatemodel. To conﬁrm the validity this ﬁnding when
the multivariate model incorporated conditioning intensity,
it remained nonsigniﬁcant (data not shown).
Multivariate analysis of acute leukemia patients (n¼ 156)
is shown in Table 5. When adjusting for gender, recipient
CMV status, diagnosis, and HCT-CI, 7/8 HLAematched URDT
was associated with inferior DFS (hazard ratio [HR], 1.91;
P ¼ .037) compared with that of DCBT. There was no differ-
ence between 8/8 HLAematched URDT and the DCBT refer-
ence group (HR, 1.43; P ¼ .257). In the same model, diagnosis
of ALL (HR, 2.09; P ¼ .004) and female gender (HR, 1.68;
P ¼ .031) had worse DFS, whereas an HCT-CI score of 3
approached signiﬁcance (P ¼ .092).DISCUSSION
The standard HSC source for adult patients with high-risk
hematologic malignancies who require an allograft and lack
an HLA-matched related donor is an 8/8 HLAematched un-
related volunteer donor andmany centers will consider a 7/8
HLAematched donor as the next best alternative. Multiple
approaches to prevent GVHD in URDT recipients are avail-
able. TCD, a strategy that has achieved DFS rates similar to
those of unmodiﬁed grafts [16-20,28,29] and currently under
investigation in the Bone Marrow Transplant Clinical Trials
Network, has been the priority at our institution. In this
analysis, we demonstrate that DCBT achieved a 3-year DFS
comparable to that of recipients of an 8/8 HLAematched
URDT and higher than a 7/8 HLAematched URDT when the
volunteer donor grafts are TCD.
Each transplantation modality had both advantages
and disadvantages. Engraftment speedwas amajor beneﬁt of
URDT utilizing peripheral blood HSC. Additionally, TCD
was associated with low rates of grade II to IV acute GVHD
[16-20,28,29]. The lethality of GVHD, when it occurred after
URDT, was high, however, especially when the grafts were
Table 4
Univariate and Multivariate Analysis of Variables Potentially Associated with DFS in URDT and DCBT Recipients with Acute Leukemia
A. URDT recipients
Variable 3-Year DFS (95% CI) Univariate HR (95% CI) P Value Multivariate HR* (95% CI) P Value
Recipient age .962 -
<45 Yr (n ¼ 54) 51% (37-64) Reference
45 Yr (n ¼ 57) 50% (36-62) 1.01 (.99-1.66)
Recipient gender .135 .332
Male (n ¼ 63) 56% (43-68) Reference Reference
Female (n ¼ 48) 43% (29-57) 1.49 (.88-2.51) 1.31 (.76-2.27)
Recipient CMV status .862 .597
Negative (n ¼ 50) 47% (32-60) Reference Reference
Positive (n ¼ 61) 54% (41-65) .96 (.57-1.61) 1.17 (.66-2.06)
HCT-CI score .120 .165
0-2 (n ¼ 60) 58% (44-69) Reference Reference
3 (n ¼ 51) 43% (29-56) 1.51 (.90-2.55) 1.48 (.85-2.57)
Diagnosis .011 .020
AML (n ¼ 73) 57% (45-67) Reference Reference
ALL (n ¼ 30) 30% (15-46) 2.01 (1.17-3.45) 2.00 (1.12-3.58)
Conditioning .604 -
High dose (n ¼ 79) 48% (37-59) Reference
Intermediate (n ¼ 32) 56% (37-71) .86 (.48-1.53)
HLA match .197 .275
8/8 (n ¼ 66) 57% (45-68) Reference Reference
7/8 (n ¼ 45) 41% (27-55) 1.41 (.84-2.37) 1.35 (.79-2.30)
Transplantation year .332 -
2005-2008 (n ¼ 48) 46% (31-59) 1.30 (.77-2.18)
2009-2012 (n ¼ 63) 54% (40-66) Reference
B. DCBT recipients
Variable 3-Year DFS (95% CI) Univariate HR (95% CI) P Value Multivariate HRy (95% CI) P Value
Recipient age .454 -
<45 Yr (n ¼ 31) 74% (54-86) Reference
45 Yr (n ¼ 24) 61% (37-78) 1.42 (.57-3.59)
Recipient gender .058 .024
Male (n ¼ 26) 77% (53-90) Reference Reference
Female (n ¼ 29) 59% (39-74) 2.72 (.97-7.63) 3.86 (1.19-12.49)
Recipient CMV status .146 .399
Negative (n ¼ 19) 81% (52-94) Reference Reference
Positive (n ¼ 36) 61% (43-75) 2.28 (.75-6.95) 1.61 (.53-4.89)
Recipient ancestry .833 -
European (n ¼ 25) 71% (48-85) Reference
Non-European (n ¼ 30) 65% (45-80) 1.11 (.44-2.81)
HCT-CI score .340 -
0-2 (n ¼ 24) 75% (53-88) Reference
3 (n ¼ 31) 62% (42-77) 1.61 (.61-4.30)
Diagnosis .312 .028
AML (n ¼ 36) 72% (54-84) Reference Reference
ALL (n ¼ 17) 54% (25-76) 1.64 (.63-4.24) 3.16 (1.13-8.80)
Conditioning .819 -
High dose (n ¼ 26) 69% (48-83) Reference
Intermediate (n ¼ 29) 66% (43-81) .90 (.35-2.27)
HLA match (engrafting unit)z .845 -
7/8 (n ¼ 7) 57% (17-84) Reference
5-6/8 (n ¼ 31) 71% (51-84) .70 (.19-2.54)
4/8 (n ¼ 17) 67% (36-85) .68 (.16-2.88)
Median infused CD34þ cell
dose (dominant unit)z
.458 -
<.86 (n ¼ 27) 70% (49-84) Reference
.86 (n ¼ 28) 65% (42-81) 1.42 (.56-3.61)
Transplantation year .368 -
2005-2008 (n ¼ 16) 63% (35-81) 1.56 (.59-4.08)
2009-2012 (n ¼ 39) 69% (51-82) Reference
* Patients diagnosed with CML (n ¼ 8) were excluded from the multivariate analysis.
y Patients diagnosed with CML (n ¼ 2) were excluded from the multivariate analysis.
z In patients with clinical graft failure the dominant unit based on bone marrow chimerism was used.
D.M. Ponce et al. / Biol Blood Marrow Transplant 21 (2015) 1985e19931990HLA mismatched. In DBCT recipients, the incidence of sus-
tained donor engraftment was high by CBT standards, likely
reﬂecting the unit selection, unit handling, and conditioning
employed by an experienced center. However, althoughthere were no secondary graft failures, the speed of neutro-
phil recovery was substantially delayed, likely contributing
to the increased early TRM risk. Platelet recovery was also
delayed when compared with that of URDT recipients,
Table 5
Multivariate Analysis of Variables Potentially Associated with DFS of AML
and ALL Patients (n ¼ 156)
Variable Multivariate HR (95% CI) P Value
Recipient gender .031
Male Reference
Female 1.68 (1.05-2.68)
Recipient CMV serology .217
Negative Reference
Positive 1.35 (.84-2.17)
HCT-CI score .092
0-2 Reference
3 1.51 (.94-2.45)
Diagnosis .004
AML Reference
ALL 2.09 (1.26-3.46)
Graft type
DCB Reference
8/8 HLAematched URD 1.43 (.77-2.63) .257
7/8 HLAematched URD 1.91 (1.04-3.50) .037
D.M. Ponce et al. / Biol Blood Marrow Transplant 21 (2015) 1985e1993 1991although in patients alive at day 100, all but 1 recovered
platelets, indicating that failed platelet engraftment is a
manifestation of early TRM. In this ATG-free platform,
although rates of chronic GVHD were low as previously re-
ported [22,30-32], the incidence of acute GVHD was 55%,
supporting the current investigation of measures to mitigate
severe acute GVHD after DCBT [22,33-36].
Although the 3-year incidences of TRM were similar in
recipients of TCD URDT and DCBT, the patterns of TRM were
different. URDT recipients had a delayed and prolonged TRM
risk that was worse with mismatched grafts. By contrast,
nearly all of the TRM after DCBT was early after trans-
plantation. Moreover, despite DCBT recipients having similar
disease risk, percentages of minimal residual disease before
transplantation, and a lower percentage of patients receiving
high-dose conditioning, the likelihood of relapse was
signiﬁcantly reduced, suggesting CB has a robust graft-
versus-leukemia effect. This is consistent with previous
comparisons of unmodiﬁed URDT and DCBT [6] and re-
inforces the observation that relapse protection is a major
advantage of DCBT in adults. Whether this graft-versus-
leukemia effect requires a double-unit graft or is inherent
in CB as an HSC source remains to be established, however,
especially in the setting of intermediate- or reduced-
intensity conditioning.
Multivariate analysis of factors associated with treatment
failure by HSC source demonstrated that the most signiﬁcant
adverse patient or graft characteristic in URDT recipients was
a diagnosis of ALL. In recipients of DCBT, despite marked HLA
mismatch and low cell dose, neither the dominant unit
donor-recipient HLA match nor its infused CD34þ cell dose
inﬂuenced DFS, but multivariate analysis revealed a worse
outcome in female patients and those with ALL. In the
multivariate analysis of DFS in all acute leukemia patients, 7/8
HLAematched URDT was associated with inferior DFS
compared to that of DCBT. Female gender and a diagnosis of
ALL also had a higher risk of treatment failure. There was a
trend toworse DFSwith high comorbidity scores. The ﬁnding
that female gender was associated with inferior DFS was
neither expected nor explained and requires further
investigation.
Overall, this analysis serves to emphasize the major ob-
stacles to success in TCD URDT and DCBT. In URDT recipients
undergoing TCD, mortality from infection and relapse sug-
gests that the lack of effective immune reconstitution is the
major challenge. It is likely that the small number of patientswho do develop GVHD in this setting have increased mor-
tality due to delayed immune recovery being exacerbated by
the need for additional immunosuppression. Strategies to
augment immune recovery are under investigation [37,38].
In contrast, DCBT recipients are most compromised by early
TRM due to delayed engraftment, organ toxicity, and acute
GVHD. Numerous strategies to mitigate these complications,
such as improved CB graft selection with consideration of
CD34þ cell dose [7,8] and high-resolution HLA match
[22,39,40], augmentation of engraftment (improved homing,
ex vivo expansion or coinfusion of third-party progenitors)
[41-47], reduced-toxicity preparative regimens [21,31,48-50],
augmented GVHD prophylaxis [35,36,51], and intensive
supportive care [52-54], are being investigated and will be
assisted by an increase in the size of the global CB inventory.
This analysis has the limitations of a retrospective study
and that the URDT population is composed exclusively of
TCD grafts. These ﬁndings, therefore, require conﬁrmation in
a larger prospective study of DCB and URD transplantations
including URD grafts that are unmodiﬁed. Nonetheless, in
the interim, that CB grafts extend transplantation access to
minorities is evident from this study, and that non-European
DCBT recipients had comparable DFS to those with European
origin is an important additional ﬁnding that warrants a
larger analysis. With a follow-up of approximately 4 years,
our analysis has implications for donor algorithms and the
allocation of resources to URD registries versus public CB
banks. DCB grafts can be rapidly secured especially if CB is
pursued at the outset of the search. Our data, combined with
similar previous studies comparing DCBT with unmodiﬁed
URDT recipients [6], would support DCBT being considered
as a readily available therapy for high-risk acute leukemia in
adult patients 60 years, especially in those without a
readily available 8/8 allele HLAematched volunteer donor.ACKNOWLEDGMENTS
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